DT2216 | BCL-XL PROTAC Degrader |CAS 2365172-42-3| DC Chemicals

Cas No.:	2365172-42-3
Chemical Name:	DT-2216
Synonyms:	DT2216;DT-2216;DT 2216
SMILES:	CC1(CC(CN2CCN(C3C=CC(C(=O)NS(=O)(C4C=CC(N[C@H](CCN5CCN(C(=O)CCCCCC(=O)N[C@H](C(=O)N6C[C@H](O)C[C@H]6C(=O)N[C@@H](C)C6C=CC(C7SC=NC=7C)=CC=6)C(C)(C)C)CC5)CSC5C=CC=CC=5)=C(S(=O)(=O)C(F)(F)F)C=4)=O)=CC=3)CC2)=C(C2C=CC(Cl)=CC=2)CC1)C
Formula:	C₇₇H₉₆ClF₃N₁₀O₁₀S₄
M.Wt:	1542.36
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	[1]. Khan S, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 Dec;25(12):1938-1947.

Description:	DT2216 is a selective B-cell lymphoma extra large (BCL-XL) proteolysis-targeting chimera (PROTAC). DT2216 targets BCL-XL to the Von Hippel-Lindau (VHL) E3 ligase for degradation. DT2216 inhibits various BCL-XL-dependent leukemia and cancer cells but considerably less toxic to platelets[1].
Target:	VHL
In Vivo:	DT2216 (i.p.; 7.5, 15 mg/kg; weekly for 60 days) of 15 mg/kg is more effective at suppressing the growth of MOLT-4 T-ALL xenografts in mice than 7.5 mg/kg[1]. Animal Model: CB17/Icr-Prkdcscid/IcrIcoCrl (CB-17 SCID) mice aged 5-6 weeks[1] Dosage: 7.5, 15 mg/kg Administration: i.p.; weekly for 60 days Result: Suppressed the growth of MOLT-4 T-ALL xenografts in mice.
In Vitro:	DT2216 (62.5, 125 nM; 72 hours) kills MOLT-4 cells[1]. ABT263 (0.001-10 μM; 72 hour) shows highly toxic to MOLT-4 cells with an EC50 of 0.052 μM[1]. DT2216 (0.1, 0.3 μM; 24 hours) kills MOLT-4 cells by caspase-3-mediated induction of apoptosis in a BCL-2 homologous antagonist killer (BAK)- and BCL-2-associated X protein (BAX)-dependent manner[1]. Apoptosis Analysis[1] Cell Line: MOLT-4 cells Concentration: 62.5, 125 nM Incubation Time: 72 hours Result: Killed MOLT-4 cells. Cell Cytotoxicity Assay[1] Cell Line: MOLT-4 cells Concentration: 0.001, 0.01, 0.1, 1, 10 μM Incubation Time: 72 hours Result: Showed highly toxic to MOLT-4 cells with an EC50 of 0.052 μM. Western Blot Analysis[1] Cell Line: MOLT-4 cells Concentration: 0.1, 0.3 μM Incubation Time: 24 hours Result: Killed MOLT-4 cells by caspase-3-mediated induction of apoptosis in a BCL-2 homologous antagonist killer (BAK)- and BCL-2-associated X protein (BAX)-dependent manner.
References:	[1]. Khan S, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 Dec;25(12):1938-1947.

Cat. No.	Product name	Field of application
DC65211	KT-474	KT-474 is a highly active and selective, orally bioavailable IRAK4 degrader being developed for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven immune-inflammatory diseases.
DC39826	Homo-PROTAC cereblon degrader 1	Homo-PROTAC cereblon degrader 1, is a cereblon degrader.
DC74523	XY-07-35	XY-07-35 is a potent, selective HDAC6 proteolysis targeting chimera (PROTAC) degrader with IC50 of 48.5 nM.
DC74496	HJM-561	HJM-561 is a potent, selective and orally bioavailable EGFR PROTAC degrader, selectively degrades the EGFR C797S-containing triple mutants Del19/T790M/C797S and L858R/T790M/C797S with DC50 values of 9.2 nM and 5.8 nM, respectively.
DC74494	GNE-0011	GNE-0011 is a monovalent, JQ1-based BRD4 degrader that is not linked to an E3 ligase binder, triggers proteasomal and ubiquitin-dependent selective degradation of BRD4 over BRD2 and BRD3.
DC74479	BSJ-05-037	BSJ-05-037 is a potent and selective heterobifunctional degrader of ITK with DC50 of 17.6-41.8 nM in TCL lines DERL-2 and Hut78.
DC72756	JQAD1	JQAD1 is a CRBN-dependent PROTAC that selectively targets EP300 for degradation. JQAD1 suppresses EP300 expression and the H3K27ac modification. JQAD1 induces apoptosis. JQAD1 can be used in research of cancer.
DC48434	TD-165	TD165(TD 165) is a PROTAC-based cereblon (CRBN) degrader that degrads Cav1.2α with the DC50 of 20.4 nM, comprising a cereblon (CRBN) ligand binding group, a linker and an von Hippel-Landau (VHL) binding group.
DC46405	ARD-2128	ARD2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer.
DC46309	Boc-piperazine-benzoic acid	Boc-piperazine-benzoic acid is a PROTAC linker and can be used in the synthesis of PROTACs, such as PROTAC androgen receptor (AR) degrader ARD-2128.